KIMBERLY-CLARK ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE I-FLOW CORPORATION
Scripps Research Scientists Illuminate Structure of Circulating Lung Cancer Cells
Almirall aims to file once daily aclidinium bromide for COPD in Europe in early 2010
Aeolus Pharmaceuticals' AEOL 10150 Protects Lungs Against Mustard Gas Exposure in Animal Studies
Notice of Annual Report and Accounts and Annual General Meeting7
To keep up to date with news from this category use our
Cornerstone Therapeutics Reports Third Quarter 2009 Financial Results
CARY, N.C., Nov. 4 -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related...
Enobia Pharma Expands Clinical Program for ENB-0040, a Bone-Targeted Enzyme Replacement Therapy for Hypophosphatasia
MONTREAL, November 3, 2009 -- Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia...
MediciNova Announces Initiation of a Phase Ib Clinical Trial for MN-221 in Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease
SAN DIEGO, November 3, 2009 -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:...
Alfacell Corporation Announces Closing of $3.25 Million Private Placement
SOMERSET, N.J., Oct. 20, 2009 -- Alfacell Corporation (Pink Sheets:ACEL) today announced that it has closed a private placement with certain investors in which it raised $3.25 million in gross proceeds through the sale...
Notice of Annual Report and Accounts and Annual General Meeting7
Southampton, UK - 14 October 2009: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a particular focus on viral defence in asthma and chronic obstructive pulmonary disease ('COPD'),...
Scripps Research Scientists Illuminate Structure of Circulating Lung Cancer Cells
LA JOLLA, CA, October 13, 2009 - Most cancer-related deaths are caused by metastases - the spread of cancer to other parts of the body - and tumor cells that circulate in the bloodstream are generally understood to be...
KIMBERLY-CLARK ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE I-FLOW CORPORATION
DALLAS and LAKE FOREST, Calif., October 9, 2009 - Kimberly-Clark Corporation (NYSE: KMB) and I-Flow Corporation (NASDAQ: IFLO), a leading healthcare company that develops and markets technically advanced, low-cost drug...
In JCO, Danusertib results of a Phase 1 trial. Phase 2 in patients with lung cancer and other solid tumors ongoing.
Nerviano Italy, 8 October 2009 - Nerviano Medical Sciences today announced a publication in the peer-reviewed scientific journal, Journal of Clinical Oncology (*), of the first clinical trial performed in man in...
ImmunoCellular Therapeutics Announces Successful Humanization of Two Antibody Candidates
LOS ANGELES, CA -October 08, 2009 - ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers,...
Aeolus Pharmaceuticals' AEOL 10150 Protects Lungs Against Mustard Gas Exposure in Animal Studies
Mission Viejo, CA, October 7, 2009-- Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) reported that researchers from National Jewish Health and Lovelace Respiratory Research Institute have completed a series of...
ARQULE PROVIDES CLINICAL UPDATE ON ARQ 197
WOBURN, Mass.--Oct. 5, 2009ArQule, Inc. (Nasdaq: ARQL) today announced that patient enrollment in a Phase 2 trial with ARQ 197 in non-small cell lung cancer (NSCLC) has been completed.
ResMed Acquires Laboratoires Narval
SAN DIEGO, Oct. 5, 2009 -- ResMed Inc. (NYSE: RMD), a leading developer, manufacturer and distributor of sleep and respiratory medical equipment, announced today that it has acquired Laboratoires Narval. Based in...
Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation
BERLIN- September 24, 2009 -Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy...
Cepheid Receives FDA Clearance for Xpert
Sunnyvale, CA and Bedford, MA -- September 24, 2009 -- Cepheid (NASDAQ: CPHD) and Instrumentation Laboratory (IL) today announced that Cepheid has received clearance from the U.S. Food & Drug Administration (FDA) to...
Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
SOUTH SAN FRANCISCO, Calif., Sept 15, 2009 -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that 320 evaluable events (patient deaths) have occurred in its pivotal Phase 3 SPEAR (Study of Picoplatin...
PTC THERAPEUTICS INITIATES REGISTRATION-DIRECTED PHASE 3 TRIAL OF ATALUREN IN CYSTIC FIBROSIS
SOUTH PLAINFIELD, NJ - September 10, 2009 - PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124
Almirall aims to file once daily aclidinium bromide for COPD in Europe in early 2010
Barcelona, 9th September 2009.- Almirall, S.A. (ALM.MC) today announced its intention to file a Marketing Authorization Application (MAA) with the European Medicines Agency (EMEA) for its once-daily long acting...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
